Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
03. August 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations
27. Juli 2023 16:05 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference
27. Juli 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
13. Juli 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting
29. Juni 2023 07:00 ET
|
Plus Therapeutics Inc.
ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation dose ReSPECT-LM Phase 1/Part A leptomeningeal metastases trial...
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
14. Juni 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting
08. Juni 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, June 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Provides Company Update Today
01. Juni 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023
30. Mai 2023 07:00 ET
|
Plus Therapeutics Inc.
Plus Therapeutics’ partnership with Medidata resulted in a valid historical control arm for the Company’s Phase 1/2 clinical and potential Phase 3 trials evaluating rhenium (186Re) obisbemeda in...
Plus Therapeutics to Present at the 2023 Virtual June Investor Summit
25. Mai 2023 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...